GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

NCT02095184 · clinicaltrials.gov ↗

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped This study was terminated due to slow accrual, and this due to the changing practice patterns, and difficulties with insurance coverage for some of the study related tests, such as OncotypeDx.

Conditions

Breast Cancer

Interventions

DRUG: Anastrozole
DRUG: Letrozole

Sponsor

University of Maryland, Baltimore